ArticleStem cell research & therapy2025
Ontogenetic stage and type of donor cells shape extracellular vesicles' therapeutic potential for osteoarthritis.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From pathogenic to reparative: Context-Dependent function of extracellular vesicles in osteoarthritis.Bioactive materials · 2027Review
- MSC-EVs in Cartilage Regeneration and Immunomodulation: Mechanisms and Therapeutic Prospects for Osteoarthritis, Rheumatoid Arthritis and Intervertebral Disc Degeneration.International journal of molecular sciences · 2026Review
- Chromatin remodeling and epigenetic regulation of mesenchymal stem/stromal cells in osteoarthritis.Frontiers in genetics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundOsteoarthritis (OA) remains an intractable condition due to the limited regenerative capacity of adult cartilage. Extracellular vesicles (EVs) have emerged as promising therapeutics, yet the optimal donor cell source is still undetermined, as both donor cell type and age significantly influence EV therapeutic efficacy. This study evaluates the therapeutic potential of EVs derived from ovine fetal articular chondrocytes (fCCs) and ovine fetal umbilical cord blood mesenchymal stromal cells (fMSCs) compared to EVs from two immortalized human perinatal cell lines, Wharton's jelly (WJ-MSCs) and amnion MSCs (P-MSCs), on inflamed ovine adult chondrocytes and synoviocytes in vitro.
methodsEVs were isolated from conditioned media using tangential flow filtration and characterized by size, concentration, and EV markers. Inflamed adult articular chondrocytes and synoviocytes were treated with 1E + 09 particles/mL of each EV source. EV's cellular uptake was assessed via live-cell imaging, flow cytometry, and confocal microscopy. Therapeutic effects were evaluated through proliferation, wound healing assays, and multi-omics (RNASeq, proteomics) analyses at 24 and 48 h post-treatment.
resultsAll EVs were successfully internalized by inflamed ovine and human chondrocytes. Donor cell type significantly influenced incorporation with fCC-EVs achieving the highest uptake across conditions. All treatments reduced pro-inflammatory genes and upregulated growth and cell cycle-related genes. Fetal-derived EVs induced more robust transcriptional changes and enriched signaling pathways than perinatal-derived EVs. Notably, fCC-EVs exhibited the most pronounced effects on inflamed chondrocytes, while fMSC-EVs were most effective on synoviocytes. Donor cell age emerged as a more influential factor in therapeutic efficacy than cell type.
conclusionsThe ontogenetic stage of donor cells plays a crucial role in EV's therapeutic efficacy, with fetal-derived EVs demonstrating superior outcomes compared to perinatal-derived EVs. The distinct effects of fCC-EVs and fMSC-EVs suggest that a combinatorial approach using both EV types could optimize therapeutic outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.